Sigyn Therapeutics, Inc. 8-K

What Happened

• Sigyn Therapeutics, Inc. announced it entered into three one-year Convertible Note Purchase Agreements in February 2026 with Brio Capital Master Fund, Ltd., Osher Capital Partners, LLC, and Lambda Venture Partners, LLC. The agreements have aggregate principal amounts of $72,222.21 and resulted in $61,500 of cash proceeds to the company. The notes bear interest at 8% per annum and are convertible, at the holder’s option, into Sigyn common stock at a conversion price equal to a 35% discount to the lowest traded price during the 20 trading days immediately before a conversion notice.

Key Details

• Counterparties and principals: Brio Capital ($22,222.22), Osher Capital ($22,222.22), Lambda Venture Partners ($27,777.77).
• Cash proceeds received: $20,000 (Brio), $20,000 (Osher), $21,500 net (Lambda, after legal fees) — total $61,500.
• Terms: 1‑year maturity, 8% annual interest, convertible at holder option at a 35% discount to the lowest traded price in the 20 trading days before conversion notice; no stock purchase warrants issued.
• Securities issued in reliance on Section 4(a)(2) of the Securities Act (private placement to sophisticated investors).

Why It Matters

• This filing documents short‑term financing that provides Sigyn with $61,500 in cash to support operations or corporate needs in the near term.
• The convertible feature could lead to future dilution if holders convert, because conversion is at a substantial (35%) discount to recent trading prices.
• The notes mature in one year and carry an 8% interest cost, so investors should watch for potential conversion activity, repayment, or additional financing disclosures within the coming year.